Vancouver, B.C. – May 31, 2021: NeonMind Biosciences Inc. (CSE: NEON) (OTCQB: NMDBF) (FRA: 6UF) (“NeonMind” or the “Company”), an integrated drug development and wellness company focused on the potential therapeutic uses of psilocybin for treating obesity and weight management conditions, is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders (the “Meeting”) held on May 27, 2021 at the offices of Wildeboer Dellelce LLP, Wildeboer Dellelce Place, 365 Bay Street, Suite 800, Toronto, Ontario M5H 2V1.

At the Meeting, all matters put forward before shareholders for consideration and approval as set out in the Company’s Notice of Meeting and Management Information Circular, dated April 16, 2021, were approved by an overwhelming majority of votes cast at the Meeting by the Shareholders as follows:

NUMBER OF DIRECTORS

The Shareholders approved the setting of the number of directors at three.

ELECTION OF DIRECTORS

The Shareholders elected the following slate of directors:

Penny White
Jeff Smith
Kari Richardson

APPOINTMENT OF AUDITORS

The Shareholders re-appointed the current auditors, Saturna Group Chartered Professional Accountants LLP, as auditors of the Company for the ensuing year, with their remuneration to be fixed by the Company’s Board of Directors.

AMENDED AND RESTATED STOCK OPTION PLAN

The Shareholders ratified and approved the Company’s amended and restated stock option plan.

AMENDED AND RESTATED RESTRICTED SHARE UNIT PLAN

The Shareholders ratified and approved the Company’s amended and restated restricted share unit plan.

Detailed voting results are contained in the “Report of Voting Results” for the Meeting, which is available under NeonMind’s profile on SEDAR at www.sedar.com.

 

About NeonMind Biosciences Inc.

NeonMind is engaged in preclinical research to develop potential clinical treatments and wellness products to address obesity and weight management conditions and to promote health and wellness. The Company operates three divisions: (i) a pharmaceutical division engaged in drug development of psychedelic compounds with two lead psilocybin-based drug candidates targeting obesity; (ii) a medical services division focused on launching specialty mental health clinics that integrate psychedelic therapeutics into traditional psychotherapy settings; and (iii) a consumer products division that currently sells mushroom-infused products to promote health and wellness.

In its pharmaceutical division, NeonMind has two distinct psilocybin drug development programs targeting obesity. NeonMind’s first drug candidate employs psilocybin as an agonist to the serotonin receptor 5- HT2A, which is involved in the hallucinogenic effect of psychedelics. The Company’s second drug candidate employs low-dose psilocybin as an agonist to the 5-HT2C receptor, which controls appetite.

NeonMind established a medical services division with the goal of launching NeonMind-branded specialty mental health clinics in Canada that incorporate evidence-backed innovative treatments to address a variety of mental health needs.

NeonMind’s consumer division currently sells NeonMind branded coffee products in Canada through NeonMind’s direct to consumer e-commerce platform, and it has plans to launch dietary supplements in the United States in the near future.

For more information on NeonMind, go to www.NeonMindBiosciences.com.

 

Rob Tessarolo, President & Chief Executive Officer, NeonMind Biosciences Inc.

rob@neonmind.com

Tel: 416-750-3101

 

 Investor Relations:

Edge Communications

invest@neonmind.com

Tel: 1-866-318-6874

 

Scott Eckstein/Tim Regan, KCSA Strategic Communications

neonmind@kcsa.com

Tel: 212-896-1210

 

 

Media Inquiries:

Annie Graf, KCSA Strategic Communications

neonmind@kcsa.com

Tel: 786-390-2644

 

The Canadian Securities Exchange has not reviewed, approved nor disapproved the contents of this news release.

 

Cautionary Statement Regarding Forward-Looking Statements

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or NeonMind’s future performance. The use of any of the words “could”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on NeonMind’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, NeonMind’s drug development plans, its ability to retain key personnel, and its expectation as to the development of its intellectual property and other steps in its preclinical and clinical drug development constitute forward-looking information. Actual results and developments may differ materially from those contemplated by forward-looking information. Readers are cautioned not to place undue reliance on forward-looking information. The statements made in this press release are made as of the date hereof. NeonMind disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as may be expressly required by applicable securities laws.